BIOMAT Database Logo BIOMAT Database Logo

Early Pseudomonas aeruginosa colonisation in cystic fibrosis patients. 2002

Giovanni Taccetti, and Teresa Repetto, and Elena Procopio, and Silvia Farina, and Silvia Campana

UI MeSH Term Description Entries
D008297 Male Males
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D014031 Tobramycin An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species. Nebramycin Factor 6,Brulamycin,Nebcin,Nebicin,Obracin,Tobracin,Tobramycin Sulfate,Sulfate, Tobramycin

Related Publications

Giovanni Taccetti, and Teresa Repetto, and Elena Procopio, and Silvia Farina, and Silvia Campana
Early Pseudomonas aeruginosa colonisation in cystic fibrosis patients.
February 2002, Lancet (London, England),
Giovanni Taccetti, and Teresa Repetto, and Elena Procopio, and Silvia Farina, and Silvia Campana
Treatment of pseudomonas aeruginosa colonisation in cystic fibrosis.
July 1989, Archives of disease in childhood,
Giovanni Taccetti, and Teresa Repetto, and Elena Procopio, and Silvia Farina, and Silvia Campana
Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.
September 2001, Lancet (London, England),
Giovanni Taccetti, and Teresa Repetto, and Elena Procopio, and Silvia Farina, and Silvia Campana
Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment.
September 1991, Lancet (London, England),
Giovanni Taccetti, and Teresa Repetto, and Elena Procopio, and Silvia Farina, and Silvia Campana
Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis.
April 1985, Lancet (London, England),
Giovanni Taccetti, and Teresa Repetto, and Elena Procopio, and Silvia Farina, and Silvia Campana
Genetic determinants of airways' colonisation with Pseudomonas aeruginosa in cystic fibrosis.
January 1993, Lancet (London, England),
Giovanni Taccetti, and Teresa Repetto, and Elena Procopio, and Silvia Farina, and Silvia Campana
Molecular epidemiology of chronic pulmonary colonisation by Pseudomonas aeruginosa in cystic fibrosis.
January 1993, Journal of medical microbiology,
Giovanni Taccetti, and Teresa Repetto, and Elena Procopio, and Silvia Farina, and Silvia Campana
Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis.
September 2010, Paediatric respiratory reviews,
Giovanni Taccetti, and Teresa Repetto, and Elena Procopio, and Silvia Farina, and Silvia Campana
Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.
September 2005, The European respiratory journal,
Giovanni Taccetti, and Teresa Repetto, and Elena Procopio, and Silvia Farina, and Silvia Campana
Early antibiotic treatment of pseudomonas aeruginosa colonisation in cystic fibrosis: a critical review of the literature.
April 2004, European journal of clinical pharmacology,
Copied contents to your clipboard!